Amy Ronneberg is the CEO of NMDP, a $900 million cell therapy organization, where she is responsible for setting the overall strategic direction and leading an organization of 2100 professionals and thousands of volunteers dedicated to creating a world where every patient can receive their life-saving cell therapy.

Amy joined NMDP in July 2013 as the Chief Financial Officer. She was responsible for planning, implementing, and directing NMDP finances, facilities, and real estate management, and reporting. As CFO, Amy partnered with and advised NMDP executives and the board of directors in developing and implementing an operating and financial business plan to meet the changing health care environment. Along with her finance duties, Amy was president of NMDP BioTherapiesSM. She led new business development while overseeing the creation and delivery of a strategic plan to grow and expand our portfolio of product offerings.

Prior to joining NMDP, Amy spent 12 years at Capella Education Company, where she served in leadership roles including chief accounting officer, vice president of finance, and vice president of operations. She also worked for Ernst & Young for several years as an audit manager.

Amy has served on many boards, including Magenta Therapeutics (MGTA), Actuate Therapeutics (ACTU), and Allina Health, a $5 billion healthcare system that recently announced its merger with Sutter Health. She earned a Master of Business Administration from Capella University in Minneapolis, Minn., a Bachelor of Business Administration in Accounting from the University of Wisconsin-Eau Claire, and her Corporate Directorship Certificate from Harvard Business School.

Boards: Actuate Therapeutics (ACTU), Allina Health, Medical Alley Association